{"nctId":"NCT01516736","briefTitle":"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","startDateStruct":{"date":"2012-03"},"conditions":["Chemotherapy-induced Neutropenia","Breast Cancer"],"count":308,"armGroups":[{"label":"LA-EP2006","type":"EXPERIMENTAL","interventionNames":["Drug: LA-EP2006"]},{"label":"Neulasta®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Neulasta®"]}],"interventions":[{"name":"LA-EP2006","otherNames":["pegfilgrastim"]},{"name":"Neulasta®","otherNames":["pegfilgrastim","Neulasta"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* histologically proven breast cancer\n* eligible for six cycles of neoadjuvant or adjuvant chemotherapy\n\nExclusion Criteria:\n\n* concurrent or prior chemotherapy for breast cancer\n* concurrent or prior anti-cancer treatment for breast cancer such as endocrine therapy, immunotherapy, monoclonal antibodies, and/or biological therapy\n* concurrent prophylactic antibiotics\n* previous therapy with any G-CSF (granulocyte-colony stimulating factor) product\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy","description":"Mean duration of severe neutropenia, defined as number of consecutive days with ANC \\<0.5 × 10\\^9/l (grade 4 neutropenia).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"1.133"},{"groupId":"OG001","value":"1.19","spread":"0.984"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"1.141"},{"groupId":"OG001","value":"1.19","spread":"0.991"}]}]}]},{"type":"SECONDARY","title":"Incidence of Febrile Neutropenia (FN)","description":"FN was defined as oral temperature ≥ 38.3°C while having an absolute neutrophil count (ANC) \\< 0.5 × 10\\^9 cells/L. Serious treatment-emergent adverse events (TEAEs) were reconciled with the fever and ANC results recorded in the patient diary and CRF and therefore only the serious TEAEs of FN (\"febrile neutropenia\", \"neutropenic sepsis\") were taken into account.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With at Least One Episode of Fever by Cycle and Across All Cycles","description":"Fever was defined as an oral body temperature of ≥ 38.3°C. Fever episodes were described by maximum oral temperature and the number of patients who had fever at least once.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Depth of ANC Nadir in Cycle 1","description":"The depth of ANC nadir was defined as the patient's lowest ANC (10\\^9 cells/L) in Cycle 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.490","spread":"0.7205"},{"groupId":"OG001","value":"0.444","spread":"0.5684"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With ANC Nadir Per Day in Cycle 1","description":"Numbers of patients with ANC nadir based per day during Cycle 1 are given.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to ANC Recovery in Days in Cycle 1","description":"Time to absolute neutrophil count (ANC) recovery was defined as the time in days from ANC nadir until the patient's ANC had increased to ≥ 2 × 10\\^9 cells/L after the nadir in Cycle 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"0.889"},{"groupId":"OG001","value":"2.04","spread":"0.951"}]}]}]},{"type":"SECONDARY","title":"Frequency of Infections by Cycle and Across All Cycles","description":"The number of patients with infections was recorded for each cycle and across all cycles. Infections were identified by the AE documentation page selecting all events coded with System Organ Class \"Infections and Infestations\".","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Due to Infection","description":"Number of patients with death due to infections","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"153","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":155},"commonTop":["Gastrointestinal disorders","General disorders and administration site conditions","Skin and subcutaneous tissue disorders","Blood and lymphatic system disorders","Musculoskeletal and connective tissue disorders"]}}}